Phaseline

Companies › Tanabe Pharma

Tanabe Pharma: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 3; Oncology, Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dersimelagon (MT-7117)
Melanocortin receptor 1 agonist
MC1RPhase 3EPPDec 2027
Inebilizumab (MT-0551)
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Systemic Sclerosis–
Loncastuximab Tesirine (MT-2111)
B-lymphocyte antigen CD19 binding agent
CD19Phase 1Diffuse Large B-Cell LymphomaAug 2028
MT-4561–Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC)Aug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05198557Inebilizumab (MT-0551)Phase 3Systemic SclerosisImmunologyJul 2025
NCT05005975Dersimelagon (MT-7117)Phase 3EPPImmunologyDec 2027
NCT05658562Loncastuximab Tesirine (MT-2111)Phase 1Diffuse Large B-Cell LymphomaOncologyAug 2028
NCT06943521MT-4561Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC)OncologyAug 2028

Targets

CD19 (2) MC1R (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Companies built like this

Antengene Biologics Beijing Mabworks Biotech Taizhou Mabtech Pharmaceutical Ganzhou Hemay Pharmaceutical Tavotek Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.